Patritumab, CAS 1262787-83-6

Product Description: Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors[1].

Applications: Cancer-Kinase/protease

Formula: N/A

References: [1]Kawakami H, et al. The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells. Oncotarget. 2014 Dec 15;5(23):11847-56.

CAS Number: 1262787-83-6

Molecular Weight: N/A

Compound Purity: 98.94

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: Akt;EGFR;ERK;PARP;Survivin

• Artikelnummer: MEXHY-P99275-10
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99275-10
• Green Labware: Nein
• Verpackungseinheit: 10 mg
• Mengeneinheit: STK